ALX Oncology presented updated data from its ASPEN-06 Phase 2 clinical trial, evaluating evorpacept, an investigational CD47-blocker, in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer, at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The data were the focus of a virtual event hosted by ALX Oncology on January 23, 2025.
The ASPEN-06 trial (Abstract #332) is a phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC). The oral presentation at ASCO GI was delivered by Kohei Shitara, M.D., Director of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan.
Evorpacept's Potential
Evorpacept, ALX Oncology's lead therapeutic candidate, has shown potential as a cornerstone therapy in immuno-oncology. It is currently being evaluated in multiple clinical trials across a range of cancer indications. The ASPEN-06 trial specifically targets patients with HER2-positive advanced gastric cancer or gastroesophageal junction cancer who have already undergone previous treatments.
Trial Design and Objectives
The ASPEN-06 trial is designed as a randomized phase 2 study, with a subsequent phase 3 portion. The primary endpoint is to assess the efficacy and safety of evorpacept in combination with other therapies in this patient population. Secondary endpoints include evaluating overall survival, progression-free survival, and objective response rate.
Virtual Event Details
During the virtual company conference call and webcast event for investors, ALX Oncology leadership reviewed the updated ASPEN-06 data. The webcast provided access to the presentation and a replay is available on ALX Oncology's website in the "Investors" section under "Events and Presentations."
